Jack Allen
Stock Analyst at Baird
(0.78)
# 3,646
Out of 4,771 analysts
42
Total ratings
32.35%
Success rate
-18.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CARM Carisma Therapeutics | Downgrades: Neutral | $10 → $1 | $0.40 | +149.56% | 3 | Dec 12, 2024 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $8.24 | +385.44% | 2 | Nov 15, 2024 | |
| VOR Vor Biopharma | Maintains: Outperform | $22 → $14 | $0.83 | +1,592.87% | 3 | Nov 8, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $77 → $106 | $69.87 | +51.71% | 5 | Nov 6, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $24 → $18 | $9.19 | +95.87% | 2 | Oct 25, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $20.99 | +757.55% | 9 | Sep 16, 2024 | |
| BLUE bluebird bio | Maintains: Outperform | $140 → $120 | $3.94 | +2,945.69% | 3 | Aug 15, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $2.54 | +214.96% | 1 | Jun 13, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $46 → $52 | $40.97 | +26.92% | 2 | May 9, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $84 | $28.38 | +196.04% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $1.74 | +359.77% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $1.69 | +610.06% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $0.49 | +913.79% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $0.92 | +2,941.83% | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.27 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.89 | +131.36% | 1 | Oct 7, 2021 |
Carisma Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: $10 → $1
Current: $0.40
Upside: +149.56%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $8.24
Upside: +385.44%
Vor Biopharma
Nov 8, 2024
Maintains: Outperform
Price Target: $22 → $14
Current: $0.83
Upside: +1,592.87%
Arcellx
Nov 6, 2024
Maintains: Outperform
Price Target: $77 → $106
Current: $69.87
Upside: +51.71%
Intellia Therapeutics
Oct 25, 2024
Maintains: Neutral
Price Target: $24 → $18
Current: $9.19
Upside: +95.87%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $20.99
Upside: +757.55%
bluebird bio
Aug 15, 2024
Maintains: Outperform
Price Target: $140 → $120
Current: $3.94
Upside: +2,945.69%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $2.54
Upside: +214.96%
CRISPR Therapeutics AG
May 9, 2024
Maintains: Neutral
Price Target: $46 → $52
Current: $40.97
Upside: +26.92%
Immunocore Holdings
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $28.38
Upside: +196.04%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $8
Current: $1.74
Upside: +359.77%
Jan 6, 2023
Upgrades: Outperform
Price Target: $12
Current: $1.69
Upside: +610.06%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $0.49
Upside: +913.79%
Jun 3, 2022
Initiates: Neutral
Price Target: $28
Current: $0.92
Upside: +2,941.83%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $1.27
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.89
Upside: +131.36%